Tags

Type your tag names separated by a space and hit enter

Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study.
Int J Epidemiol. 2021 Jul 19 [Online ahead of print]IJ

Abstract

BACKGROUND

We aimed to estimate the seropositivity to anti-SARS-CoV-2 antibodies in May-June 2020 after the first lockdown period in adults living in three regions in France and to identify the associated risk factors.

METHODS

Between 4 May 2020 and 23 June 2020, 16 000 participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE) (two regions with high rate of COVID-19) or in the Nouvelle-Aquitaine (NA) (with a low rate) were randomly selected to take a dried-blood spot for anti-SARS-CoV-2 antibodies assessment with three different serological methods (ClinicalTrial Identifier #NCT04392388). The primary outcome was a positive anti-SARS-CoV-2 ELISA IgG result against the spike protein of the virus (ELISA-S). Estimates were adjusted using sampling weights and post-stratification methods. Multiple imputation was used to infer the cumulative incidence of SARS-CoV-2 infection with adjustments for imperfect tests accuracies.

RESULTS

The analysis included 14 628 participants, 983 with a positive ELISA-S. The weighted estimates of seropositivity and cumulative incidence were 10.0% [95% confidence interval (CI): 9.1%, 10.9%] and 11.4% (95% CI: 10.1%, 12.8%) in IDF, 9.0% (95% CI: 7.7%, 10.2%) and 9.8% (95% CI: 8.1%, 11.8%) in GE and 3.1% (95% CI: 2.4%, 3.7%) and 2.9% (95% CI: 2.1%, 3.8%) in NA, respectively. Seropositivity was higher in younger participants [odds ratio (OR) = 1.84 (95% CI: 1.79, 6.09) in <40 vs 50-60 years old and OR = 0.56 (95% CI: 0.42, 0.74) in ≥70 vs 50-60 years old)] and when at least one child or adolescent lived in the same household [OR = 1.30 (95% CI: 1.11, 1.53)] and was lower in smokers compared with non-smokers [OR = 0.71 (95% CI: 0.57, 0.49)].

CONCLUSIONS

Seropositivity to anti-SARS-CoV-2 antibodies in the French adult population was ≤10% after the first wave. Modifiable and non-modifiable risk factors were identified.

Authors+Show Affiliations

Sorbonne Université, Inserm, Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Paris, France. Département de Santé Publique, APHP.Sorbonne Université, Paris, France.Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille, France.Santé publique France, Saint-Maurice, France.Fondation Jean Dausset-CEPH (Centre d'Etude du Polymorphisme Humain), CEPH-Biobank, Paris, France.Sorbonne Université, Inserm, Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Paris, France. Département de Santé Publique, APHP.Sorbonne Université, Paris, France.CESP UMR1018, Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Villejuif, France.Paris University, Paris, France. Paris-Saclay University, Inserm UMS 11 Villejuif, France.Paris University, Paris, France. Paris-Saclay University, Inserm UMS 11 Villejuif, France.Sorbonne Paris Nord University, Inserm U1153, INRAE U1125, CNAM, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), Bobigny, France.Université Paris-Saclay, Inserm, CESP U1018, Le Kremlin Bicêtre, France. Service de Santé Publique, APHP, Paris Saclay, Le Kremlin Bicêtre, France.Santé publique France, Saint-Maurice, France.Ined, Inserm, EFS, UMS Elfe, Aubervilliers, France.Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Statistics Sorbonne Paris Cité, Inserm U1153, Paris Descartes University, Paris, France. Clinical Research Unit, Center for Clinical Investigation P1419, Cochin Broca Hôtel-Dieu Hospital, Paris, France.Université Paris-Dauphine, PSL-Research University, LEDa, Paris, France.Université Paris-Saclay, Inserm, CESP U1018, Le Kremlin Bicêtre, France. Service de Santé Publique, APHP, Paris Saclay, Le Kremlin Bicêtre, France.Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille, France.Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille, France.Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille, France.Sorbonne Université, Inserm, Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Paris, France.Sorbonne Université, Inserm, Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Paris, France.Paris University, Paris, France. Paris-Saclay University, Inserm UMS 11 Villejuif, France.Sorbonne Paris Nord University, Inserm U1153, INRAE U1125, CNAM, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), Bobigny, France.Sorbonne Paris Nord University, Inserm U1153, INRAE U1125, CNAM, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), Bobigny, France.Institut de Santé Publique, Pôle Recherche Clinique, Institut National de la Santé et de la Recherche Médicale, Paris, France.Inserm, Institut Thématique Santé Publique, Paris, France.Fondation Jean Dausset-CEPH (Centre d'Etude du Polymorphisme Humain), CEPH-Biobank, Paris, France.IRIS, Inserm/EHESS/CNRS, Aubervilliers, France.CESP UMR1018, Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Villejuif, France. Department of Statistics, Computer Science and Applications, University of Florence, Italy.Sorbonne Paris Nord University, Inserm U1153, INRAE U1125, CNAM, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris (CRESS), Bobigny, France.Paris University, Paris, France. Paris-Saclay University, Inserm UMS 11 Villejuif, France.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34293141

Citation

Carrat, Fabrice, et al. "Antibody Status and Cumulative Incidence of SARS-CoV-2 Infection Among Adults in Three Regions of France Following the First Lockdown and Associated Risk Factors: a Multicohort Study." International Journal of Epidemiology, 2021.
Carrat F, de Lamballerie X, Rahib D, et al. Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study. Int J Epidemiol. 2021.
Carrat, F., de Lamballerie, X., Rahib, D., Blanché, H., Lapidus, N., Artaud, F., Kab, S., Renuy, A., de Edelenyi, F. S., Meyer, L., Lydié, N., Charles, M. A., Ancel, P. Y., Jusot, F., Rouquette, A., Priet, S., Villarroel, P. M. S., Fourié, T., Lusivika-Nzinga, C., ... Zins, M. (2021). Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study. International Journal of Epidemiology. https://doi.org/10.1093/ije/dyab110
Carrat F, et al. Antibody Status and Cumulative Incidence of SARS-CoV-2 Infection Among Adults in Three Regions of France Following the First Lockdown and Associated Risk Factors: a Multicohort Study. Int J Epidemiol. 2021 Jul 19; PubMed PMID: 34293141.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study. AU - Carrat,Fabrice, AU - de Lamballerie,Xavier, AU - Rahib,Delphine, AU - Blanché,Hélène, AU - Lapidus,Nathanael, AU - Artaud,Fanny, AU - Kab,Sofiane, AU - Renuy,Adeline, AU - de Edelenyi,Fabien Szabo, AU - Meyer,Laurence, AU - Lydié,Nathalie, AU - Charles,Marie-Aline, AU - Ancel,Pierre-Yves, AU - Jusot,Florence, AU - Rouquette,Alexandra, AU - Priet,Stéphane, AU - Villarroel,Paola Mariela Saba, AU - Fourié,Toscane, AU - Lusivika-Nzinga,Clovis, AU - Nicol,Jérôme, AU - Legot,Stephane, AU - Druesne-Pecollo,Nathalie, AU - Esseddik,Younes, AU - Lai,Cindy, AU - Gagliolo,Jean-Marie, AU - Deleuze,Jean-François, AU - Bajos,Nathalie, AU - Severi,Gianluca, AU - Touvier,Mathilde, AU - Zins,Marie, AU - ,, Y1 - 2021/07/19/ PY - 2020/12/18/received PY - 2021/05/04/accepted PY - 2021/7/22/entrez PY - 2021/7/23/pubmed PY - 2021/7/23/medline KW - COVID-19 KW - SARS-COV-2 KW - cohort KW - general population KW - risk factors KW - seroprevalence JF - International journal of epidemiology JO - Int J Epidemiol N2 - BACKGROUND: We aimed to estimate the seropositivity to anti-SARS-CoV-2 antibodies in May-June 2020 after the first lockdown period in adults living in three regions in France and to identify the associated risk factors. METHODS: Between 4 May 2020 and 23 June 2020, 16 000 participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE) (two regions with high rate of COVID-19) or in the Nouvelle-Aquitaine (NA) (with a low rate) were randomly selected to take a dried-blood spot for anti-SARS-CoV-2 antibodies assessment with three different serological methods (ClinicalTrial Identifier #NCT04392388). The primary outcome was a positive anti-SARS-CoV-2 ELISA IgG result against the spike protein of the virus (ELISA-S). Estimates were adjusted using sampling weights and post-stratification methods. Multiple imputation was used to infer the cumulative incidence of SARS-CoV-2 infection with adjustments for imperfect tests accuracies. RESULTS: The analysis included 14 628 participants, 983 with a positive ELISA-S. The weighted estimates of seropositivity and cumulative incidence were 10.0% [95% confidence interval (CI): 9.1%, 10.9%] and 11.4% (95% CI: 10.1%, 12.8%) in IDF, 9.0% (95% CI: 7.7%, 10.2%) and 9.8% (95% CI: 8.1%, 11.8%) in GE and 3.1% (95% CI: 2.4%, 3.7%) and 2.9% (95% CI: 2.1%, 3.8%) in NA, respectively. Seropositivity was higher in younger participants [odds ratio (OR) = 1.84 (95% CI: 1.79, 6.09) in <40 vs 50-60 years old and OR = 0.56 (95% CI: 0.42, 0.74) in ≥70 vs 50-60 years old)] and when at least one child or adolescent lived in the same household [OR = 1.30 (95% CI: 1.11, 1.53)] and was lower in smokers compared with non-smokers [OR = 0.71 (95% CI: 0.57, 0.49)]. CONCLUSIONS: Seropositivity to anti-SARS-CoV-2 antibodies in the French adult population was ≤10% after the first wave. Modifiable and non-modifiable risk factors were identified. SN - 1464-3685 UR - https://www.unboundmedicine.com/medline/citation/34293141/Antibody_status_and_cumulative_incidence_of_SARS-CoV-2_infection_among_adults_in_three_regions_of_France_following_the_first_lockdown_and_associated_risk_factors:_a_multicohort_study. L2 - https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyab110 DB - PRIME DP - Unbound Medicine ER -